Critical Analysis: Solana (HSDT) & Its Peers

Solana (NASDAQ:HSDT) is one of 341 public companies in the “Financial Services” industry, but how does it contrast to its peers? We will compare Solana to related companies based on the strength of its risk, dividends, earnings, valuation, profitability, analyst recommendations and institutional ownership.

Profitability

This table compares Solana and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Solana	-1,302.78%	-41.86%	-18.53%
Solana Competitors	-412.95%	-40.67%	-5.97%

Insider & Institutional Ownership

18.6% of Solana shares are owned by institutional investors. Comparatively, 43.0% of shares of all “Financial Services” companies are owned by institutional investors. 14.4% of Solana shares are owned by company insiders. Comparatively, 21.9% of shares of all “Financial Services” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of recent recommendations for Solana and its peers, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solana	1	1	2	0	2.25
Solana Competitors	1975	6903	11650	444	2.50

Solana presently has a consensus price target of $4.00, indicating a potential upside of 90.48%. As a group, “Financial Services” companies have a potential downside of 7.82%. Given Solana’s higher probable upside, research analysts plainly believe Solana is more favorable than its peers.

Earnings and Valuation

This table compares Solana and its peers top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Solana	$6.02 million	-$40.89 million	-0.07
Solana Competitors	$6.41 billion	$1.09 billion	9.13

Solana’s peers have higher revenue and earnings than Solana. Solana is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Risk and Volatility

Solana has a beta of 1.1, suggesting that its stock price is 10% more volatile than the S&P 500. Comparatively, Solana’s peers have a beta of 2.51, suggesting that their average stock price is 151% more volatile than the S&P 500.

Summary

Solana peers beat Solana on 12 of the 13 factors compared.

About Solana

Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-implantable technologies for the treatment of symptoms caused by neurological disease or trauma. The company's product is Portable Neuromodulation Stimulator, a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. The company was incorporated in 2014 and is headquartered in Newtown, Pennsylvania.